Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iN1011-N17 Phase 1b Study in Healthy Volunteers and Post-Herpetic Neuralgia
NCT06218784Phase 1Recruiting
- Sponsor
- iN Therapeutics
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iN1011-N17 in postherpetic neuralgia (PHN) (8 arms), sponsored by iN Therapeutics. Primary endpoints: Incidence, severity, and causality of AEs and serious AEs, Incidence of Physical examination abnormalities and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
iN1011-N17
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT06218784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218784.